Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"wapps-hemo"”.
-
A RANDOMIZED WAIT-LIST, PILOT DESIGN THESIS: Feasibility of the Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Tool in Severe Hemophilia Patients Undertaking Personalized Regimen Tailoring
… running a full-scale RCT with the newly designed WAPPS-Hemo calculator in the Canadian Hemophilia community. The WAPPS-Hemo calculator is widely viewed as a beneficial tool to clinicians and patients and has the potential to optimize and tailor the prophylaxis regimen for hemophilia patients.
-
The Usability Testing of the Web Accessible Population Pharmacokinetics Service- Hemophilia
Hemophilia is a genetic disorder that is caused by deficiencies in coagulation factor VIII and factor IX. Optimal management of hemophilia requires tailoring the dose of treatment to the individual patient’s need. This tailoring is based on several clinical considerations, for example, bleeding …
-
Clinical application of the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo): proposal for a pilot study of a population pharmacokinetic approach to tailored prophylaxis in hemophilia.
… way to improve the global clinical benefit of hemophilia treatment could be adopting a tailored prophylaxis regimen. To execute a tailored prophylaxis treatment scheme is necessary the evaluation of pharmacokinetic (PK) parameters acquired after the infusion of clotting factor concentrates at …
-
Pharmacokinetic modelling of clinically relevant situations in the treatment of hemophilia A and B
Hemophilia is a congenital bleeding disorder caused by deficiency of clotting factor VIII (FVIII; hemophilia A) or IX (FIX; hemophilia B). Severe hemophilia patients have less than 1% (or 1 IU/dL) of normal factor activity, and often experience spontaneous bleeding episodes. This often occurs in …
-
Haemophilia A - In pursuit of optimised outcomes via personalised treatment
… by two population-PK tools, MyPKFiT and WAPPS-Hemo, in a cohort of male patients with severe HA treated with octocog alfa. Both web tools were able to overcome assay discrepancy and produced similar FVIII half-life estimations. However, WAPPS-Hemo generated significantly longer …
-
Pharmacokinetic and economic implications when switching between hemophilia A treatments
Hemophilia is a bleeding disorder in which the blood is unable to form clots, and is also classified as severe (defined as having an endogenous factor VIII [FVIII] concentration < 1 IU/dL, or 1%), moderate (1-5%) or mild (5-50%). Those with severe hemophilia may spontaneously bleed without physical …